Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Escalon gets FDA approval for VascuView ultrasound system
Its subsidiary, Escalon Vascular Access, plans to commence shipments of the product in the US immediately. Richard DePiano Jr, president of Escalon Medical, said: “The clearance of the
Its subsidiary, Escalon Vascular Access, plans to commence shipments of the product in the US immediately. Richard DePiano Jr, president of Escalon Medical, said: “The clearance of the
The patent describes technical improvements to the Aethlon Hemopurifier that increase the rate of capture of undesirable blood contaminants including viruses, toxins, and immunosuppressive particles associated with cancer.
The extended research license covers two new viruses one in the field of human disease, the other in the veterinary field. Vivalis has already granted Kaketsuken rights to
Teva launched generic Protonix on December 21, 2007. Wyeth’s own generic version of Protonix, a gastrointestinal drug, will be distributed by Prasco. Bernard Poussot, president and CEO of
The collaboration will focus on the implementation of a first-of-its-kind, comprehensive clinical study for the treatment of macular degeneration using Stemedica’s MCT (multiple cell technology) adult stem cells
The FDA approved the addition of the Ascendra transapical delivery system to the trial, and also granted permission to increase its trial sample size from 600 patients to
The trial has studied healthy volunteers in a single, escalating dose format, to determine the safety, dose range and pharmacokinetics of the drug candidate. The results demonstrate significant
TZP-102 is a second generation prokinetic drug that Tranzyme intends to develop for the treatment of mild-to-moderate gastroparesis and other chronic gastrointestinal motility disorders. A Phase I safety
The patent describes methods of selectively removing cancer cells ex vivo from blood stem cells and other organs using various viruses including modified vaccinia viruses, herpes simplex viruses,
Mezavant is claimed to be the first and only Health Canada approved once-daily oral formulation of mesalamine, and the first mesalamine to be approved by Health Canada for